Ulacamten（亦称 CK-4021586 或 CK-586）是一种具有口服生物利用度且高度选择性的心肌肌球蛋白抑制剂，可在不影响钙离子处理的情况下增强肌球蛋白向产力状态的转变，表现出亚微摩尔级的生化效力。在临床前模型中，Ulacamten 能改善左心室收缩功能，同时维持心肌能量效率，并最大限度减少对骨骼肌和平滑肌肌球蛋白的脱靶作用。

Myoferlin inhibitor 1 是一种新型抗胰腺癌转移药物，能够肌球蛋白发挥作用。

Kemptamide is a synthetic peptide with 13-residue.

ML-9 (free base) suppresses MLCK, PKA, and PKC activity (Ki: 4, 32, and 54 μM, respectively). ML-9 (free base) is a selective and effective inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK), and stromal interaction molecule 1 (STIM1) acti

para-amino-Blebbistatin is a more water-soluble form of (S)-4'-nitro-blebbistatin , which is a more stable and less phototoxic form of (-)-blebbistatin .1,2,3 (-)-Blebbistatin is a selective cell-permeable inhibitor of non-muscle myosin II ATPases that rapidly and reversibly inhibits Mg-ATPase activity and in vitro motility of non-muscle myosin IIA and IIB for several species (IC50s = 0.5-5 μM), while poorly inhibiting smooth muscle myosin (IC50 = 80 μM).2,3,4 Through these effects, it blocks apoptosis-related bleb formation, directed cell migration, and cytokinesis in vertebrate cells. However, prolonged exposure to blue light (450-490 nm) results in degradation of blebbistatin to an inactive product via cytotoxic intermediates, which may be problematic for its use in fluorescent live cell imaging applications.5,6 The addition of a 4'-amino group increases its water solubility, decreases the inherent fluorescence, stabilizes the molecule to circumvent its degradation by prolonged blue

MPH-220是一种口服活性的、选择性骨骼肌myosin-2抑制剂，能够促进肌肉松弛。作为一种抗痉挛药物，它用于研究痉挛和肌肉僵硬。

16-38-Thymosin β4 (cattle) 是一种具有高亲和力的非 Ca2+依赖性MLCK 激活剂。

Sevasemten为骨骼肌肌球蛋白(Myosin)的变构抑制剂，具有选择性抑制作用，其IC50值对骨骼肌球蛋白 ≤ 10 μM，而对心脏肌球蛋白则 >100 μM。

JB062是一种针对非肌肉肌球蛋白(nonmusclemyosin)的抑制剂，其IC50值对骨骼肌肌球蛋白为1.6μM、心肌肌球蛋白为5.4μM，而对平滑肌肌球蛋白II大于100μM。此化合物对人类癌细胞显示出细胞毒性，对正常细胞则无此作用。JB062在肌肉痉挛、慢性肌肉骨骼疼痛及肥厚型心肌病研究中有潜在应用价值。